These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6383321)

  • 1. How to find immunomodulators--a look backward and forward.
    Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):122-31. PubMed ID: 6383321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for chemoimmunotherapeutics, success rate and predictivity of models: a five years experience.
    Sedlacek HH; Dickneite G; Schorlemmer HU
    Behring Inst Mitt; 1986 Jun; (80):74-92. PubMed ID: 3530237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutics: a questionable or a promising project.
    Sedlacek HH; Dickneite G; Schorlemmer HU
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):99-119. PubMed ID: 3791955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvants for human vaccines].
    Bröker M; Beyer C
    Pharm Unserer Zeit; 2008; 37(1):42-51. PubMed ID: 18081081
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor models to investigate the therapeutic efficiency of immunomodulators.
    Talmadge E; Lenz BF; Collins MS; Uithoven KA; Schneider MA; Adams JS; Pearson JW; Agee WJ; Fox RE; Oldham RK
    Behring Inst Mitt; 1984 May; (74):219-29. PubMed ID: 6477354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer vaccines: challenges and outlook in the field.
    Paul S; Acres B; Limacher JM; Bonnefoy JY
    IDrugs; 2007 May; 10(5):324-8. PubMed ID: 17487784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S; Dalpke A; Heeg K
    Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotoxicology of immunomodulators.
    Descotes J
    Dev Biol Stand; 1992; 77():99-102. PubMed ID: 1426677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of antitumor immune responses.
    Mihich E
    Cancer Detect Prev Suppl; 1987; 1():399-407. PubMed ID: 3319148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminium adjuvants--in retrospect and prospect.
    Lindblad EB
    Vaccine; 2004 Sep; 22(27-28):3658-68. PubMed ID: 15315845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulation and immunodeficiency.
    Foster AP
    Vet Dermatol; 2004 Apr; 15(2):115-26. PubMed ID: 15030560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analogs of 1alpha,25-dihydroxyvitamin D3 as pluripotent immunomodulators.
    Van Etten E; Decallonne B; Verlinden L; Verstuyf A; Bouillon R; Mathieu C
    J Cell Biochem; 2003 Feb; 88(2):223-6. PubMed ID: 12520518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease.
    Sijben JW; Calder PC
    Proc Nutr Soc; 2007 May; 66(2):237-59. PubMed ID: 17466105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour models for screening immunomodulators: suppression of tumour growth by delayed hypersensitivity reactions.
    Pimm MV; Baldwin RW
    Behring Inst Mitt; 1984 May; (74):214-8. PubMed ID: 6383324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Opioids and their immunomodulatory properties].
    Blahoutová V; Zajícová A; Wilczek H; Holán V
    Cas Lek Cesk; 2003; 142(4):244-7. PubMed ID: 12841129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic bacterial infection models for BRM screening.
    Dickneite G; Schorlemmer HU; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):174-82. PubMed ID: 6383323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.